Saúde global e política externa brasileira: negociações referentes à inovação e propriedade intelectual

Abstract

Since the TRIPS Agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights) came into effect, Brazil, like other developing countries, has become more assertive in multilateral negotiations and begun to argue that the present international system of intellectual property should be better adapted to its needs and interests. In doing so, the country has emphasized that intellectual property is not a subject exclusively associated with trade, but also with public health and human rights. This paper discusses the activity of the Brazilian government in multilateral negotiations that involve public health, innovation and intellectual property. The conclusion from looking at Brazil's diplomatic activity in this area is that Brazil has been a protagonist in this debate, seeking solutions that mitigate the adverse effect of the present international intellectual property system on access to drugs, and other medical technologies, in the developing countries.

Crossroad of intellectual property rights of technology innovators and human rights: a systematic literature review

“…The scholars have a growing agreement that international trade agreements must not affect HRs in any way. The HR impact assessment of the trade agreement offers a realistic framework to reconcile the potential conflict between IPRs and HRs (Forman and MacNaughton, 2016; Lima, 2017; MacNaughton and Forman, 2015).…”

A sociologia da ciência e da tecnologia no Brasil: uma análise a partir da produção em periódicos A1 entre 2010 e 2018

“…O primeiro reúne pesquisas sobre mercado, governança de inovações e tecnologias em saúde e suas respectivas disputas. Os campos de análise deste eixo compreendem a medicina regenerativa (Acero, 2015), os diferentes sistemas de inovação em saúde (Delgado, 2016) e a governança da propriedade intelectual no mercado de medicamentos (Lima, 2017). Neste conjunto de publicações, o artigo de Adriana Petryna (2011) é exemplar, analisando a formação de um mercado global de ensaios clínicos, marcado pelo deslocamento dos experimentos para países de média e baixa renda (e.g.…”